


CFT8634

Cat. No.:	HY-145925B
CAS No.:	2704617-96-7
Molecular Formula:	C ₃₇ H ₄₅ F ₃ N ₆ O ₅
Molecular Weight:	710.79
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (140.69 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.4069 mL	7.0344 mL	14.0689 mL
	5 mM	0.2814 mL	1.4069 mL	2.8138 mL
	10 mM	0.1407 mL	0.7034 mL	1.4069 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors^{[1][2]}.

REFERENCES

- [1]. Brian A, et.al. A Phase 1/2 Study of CFT8634, a Novel Bifunctional Degradation Activating Compound (BIDACmDegradar Of BRD9, in Synovial Sarcoma and SMARCB1-null Tumors.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA